Dedicated to cell & gene therapies development and manufacturing
The world’s largest dedicated cell and gene therapies (CGT) manufacturing facility at its opening in 2018, our Houston site is now approved for commercial manufacture.
This 300,000-square-foot facility is our US centre-of-excellence for process development (PD) activities of cell therapies, gene therapies and viral vectors. The site also houses large Research & Development laboratories dedicated to developing future cell and gene therapies innovations and technologies. In 2021, the site was officially approved for commercial production of a gene therapy by the FDA.
Many of our customers start process development activities in the PD laboratories, before naturally transitioning to the cGMP manufacturing floor into one of our cGMP suites located under the same roof. We purposefully built the facility with future capacity in mind, to enable scale-up manufacturing in line with our customer’s needs, so that, together, we can make more therapies available to patients.